October 6, 2016 / 12:32 PM / 10 months ago

BRIEF-Teva and Celltrion report exclusive biosimilar commercial partnership

1 Min Read

Oct 6 (Reuters) - Teva Pharmaceutical Industries Ltd :

* Teva will pay Celltrion healthcare $160 million upfront

* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars

* Exclusive partnership to commercialize two of Celltrion's MAB biosimilar candidates in U.S. and canada

* Celltrion has responsibility for completing all clinical development and regulatory activities

* Of $160 million upfront payment, up to $60 million is refundable or creditable under certain circumstances Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below